Circulating immune complexes as possible cause for anticomplementary activity in humans with malignant melanoma

[1]  R. Gupta,et al.  Correlation between tumor burden and anticomplementary activity in sera from cancer patients , 1979, Cancer Immunology and Immunotherapy.

[2]  R. Gupta,et al.  Inhibition of mitogen-induced lymphocyte proliferation correlated to anticomplementary activity in sera from melanoma patients , 1979, Cancer Immunology, Immunotherapy.

[3]  P. Lambert,et al.  Clinical relevance of circulating immune complexes in human leukemia. Association in acute leukemia of the presence of immune complexes with unfavorable prognosis. , 1977, The Journal of clinical investigation.

[4]  D. Morton,et al.  The nature of immune complexes in human cancer sera. , 1977, Journal of immunology.

[5]  H. Wanebo,et al.  Circulating immune complexes detected by 125I-Clq deviation test in sera of cancer patients. , 1977, The Journal of clinical investigation.

[6]  R. Rossen,et al.  The C1q binding test for soluble immune complexes: clinical correlations obtained in patients with cancer. , 1977, Journal of the National Cancer Institute.

[7]  V. Go,et al.  Immunoglobulin complexes in sera of patients with malignancy , 1977, International journal of cancer.

[8]  E. Kristensen,et al.  Humoral immunity in malignant skin melanoma. Isolation of melanoma specific IgG from melanoma metastases. , 1976, European journal of cancer.

[9]  E. Holborow,et al.  MULTIPLE IMMUNE COMPLEXES AND HYPOCOMPLEMENTÆMIA IN DERMATITIS HERPETIFORMIS AND CŒLIAC DISEASE , 1976, The Lancet.

[10]  D. Hartmann,et al.  Immune Complexes in Human Melanoma: A Consequence of Deranged Immune Regulation , 1976, Scandinavian journal of immunology.

[11]  P. Lambert,et al.  The occurrence of antibodies against single-stranded DNA in the sera of patients with acute and chronic leukaemia. , 1976, Clinical and experimental immunology.

[12]  Baldwin Rw,et al.  Factors interfering with immunological rejection of tumours. , 1976 .

[13]  J. Roth,et al.  Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium. , 1976, Cancer research.

[14]  M. H. Gault,et al.  Glomerular injury in patients with neoplasia. , 1976, Annual review of medicine.

[15]  A. Theofilopoulos,et al.  The Raji cell radioimmune assay for detecting immune complexes in human sera. , 1976, The Journal of clinical investigation.

[16]  H. Müller-Eberhard,et al.  C1q deviation test for the detection of immune complexes, aggregates of IgG, and bacterial products in human serum , 1975, The Journal of experimental medicine.

[17]  R. Gupta,et al.  Suggestive evidence for in vivo binding of specific antitumor antibodies of human melanomas. , 1975, Cancer research.

[18]  K. Irie,et al.  Detection of antibody and complement complexed in vivo on membranes of human cancer cells by mixed hemadsorption techniques. , 1975, Cancer research.

[19]  J. Mowbray,et al.  DETECTION OF CIRCULATING IMMUNE COMPLEXES IN PATHOLOGICAL HUMAN SERA , 1975, The Lancet.

[20]  M. Oldstone.  Immune complexes in cancer: demonstration of complexes in mice bearing neuroblastomas. , 1975, Journal of the National Cancer Institute.

[21]  K. Irie,et al.  Evidence for in vivo Reaction of Antibody and Complement to Surface Antigens of Human Cancer Cells , 1974, Science.

[22]  J. Wallace,et al.  RENAL DEPOSITION OF SOLUBLE IMMUNE COMPLEXES IN MICE BEARING B-16 MELANOMA , 1974, The Journal of experimental medicine.

[23]  R. Seshadri,et al.  Circulating immune complexes in human neuroblastoma: Direct assay and role in blocking specific cellular immunity , 1974, International journal of cancer.

[24]  D. Lannin,et al.  Further studies on the ability of regressor sera to block cell‐mediated destruction of rous sarcomas , 1974, International journal of cancer.

[25]  G. Klein,et al.  Immune complexes associated with neoplasia: presence of Epstein-Barr virus antigen-antibody complexes in Burkitt's lymphoma. , 1974, Intervirology.

[26]  S. Eccles,et al.  Radioimmunoassay of Tumour Specific Transplantation Antigen of a Chemically Induced Rat Sarcoma: Circulating Soluble Tumour Antigen in Tumour Bearers , 1973, British Journal of Cancer.

[27]  V. Pinn,et al.  Carcinoembryonic antigen-antibody complexes in a patient with colonic carcinoma and nephrotic syndrome. , 1973, The New England journal of medicine.

[28]  R. W. Baldwin,et al.  Detection of Circulating Hepatoma D23 Antigen and Immune Complexes in Tumour Bearer Serum , 1973, British Journal of Cancer.

[29]  G. Heppner,et al.  Cell‐mediated and serum blocking reactivity to tumor antigens in patients with malignant melanoma , 1973, International journal of cancer.

[30]  I. Hellstrom,et al.  Sequential studies on cell‐mediated tumor immunity and blocking serum activity in ten patients with malignant melanoma , 1973, International journal of cancer.

[31]  M. Mardiney,et al.  Immune complex disease in the kidneys of lymphoma-leukemia patients: the presence of an oncornavirus-related antigen. , 1973, Journal of the National Cancer Institute.

[32]  E. Holborow,et al.  Circulating immune complexes in dermatitis herpetiformis. , 1973, Lancet.

[33]  P. Alexander,et al.  The Presence of Tumour Specific Membrane Antigen in the Serum of Rats with Chemically Induced Sarcomata , 1973, British Journal of Cancer.

[34]  K. Hellström,et al.  Elution of “blocking factors” from human tumors, capable of abrogating tumor‐cell destruction by specifically immune lymphocytes , 1972, International journal of cancer.

[35]  R. Herberman,et al.  Delayed cutaneous hypersensitivity reactions to membrane extracts of human tumour cells. , 1971, Clinical and experimental immunology.

[36]  I. Hellstrom,et al.  Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[37]  H. Sjögren,et al.  Blocking of cell‐mediated tumor immunity by sera from patients with growing neoplasms , 1971, International journal of cancer.

[38]  M. G. Lewis,et al.  Nephrotic syndrome in malignant disease of non-renal origin. , 1971, Lancet.

[39]  R. Winchester,et al.  Precipitin reactions of the C1q component of complement with aggregated gamma-globulin and immune complexes in gel diffusion. , 1970, Immunology.

[40]  D. Morton,et al.  Immunologic studies of human sarcomas: Additional evidence suggesting an associated sarcoma virus , 1970, Cancer.

[41]  D. Morton,et al.  Demonstration in Sarcoma Patients of Anti-tumour Antibodies which Fix Only Human Complement , 1970, Nature.

[42]  S. Broder,et al.  Immunologic enhancement of tumor xenografts by pepsin-degraded immunoglobulin. , 1969, Science.

[43]  J. Lee,et al.  The association of cancer and the nephrotic syndrome. , 1966, Annals of internal medicine.

[44]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[45]  W. J. Dixon,et al.  Introduction to Statistical Analysis , 1951 .